ARVO LIVE: Analysis of vision loss from GATHER clinical program

Ophthalmology Times® talked with Carl Danzig, MD, FASRS, at this year's ARVO meeting on the post hoc analysis for the GATHER trials regarding vision loss and patients receiving ACP 2/mg versus sham.

Video transcript

Editor’s note: This transcript has been edited for clarity.

Carl Danzig, MD, FASRS:

Hi, I'm Carl Danzig and I'm happy to be here at ARVO. I'm happy to talk about the post hoc analysis regarding vision loss in the GATHER program.

This is exciting new data that I'm presenting, and what we saw in the GATHER – in this analysis regarding the GATHER program was a decreased rate of 10, 15 and 20 letter losers in patients receiving ACP 2/mg versus sham. Well, we also saw in a separate analysis is a 56% risk reduction of persistent vision loss in patients receiving treatment versus sham. Persistent vision loss, decrease of 15 letters on two consecutive visits or more. And for the first time, what we saw was a correlation between vision loss and GA growth.

This is exciting because what we saw in this study was that patients with increased vision loss had increased GA progression. Patients in the ACP 2/mg treatment arm had decreased rate of GA progression, independent of whether or not they had vision loss. We see the potential with continued treatment of ACB 2/mg of decreasing the rate of vision loss in this patient population. We find this very exciting.